Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 4/8/2025 | $2.50 | Buy | H.C. Wainwright |
| 2/1/2023 | Buy → Hold | The Benchmark Company | |
| 2/17/2022 | $8.00 → $7.00 | Overweight | Cantor Fitzgerald |
| 11/16/2021 | $10.00 → $9.00 | Buy | Aegis Capital |
4 - VOLITIONRX LTD (0000093314) (Issuer)
4 - VOLITIONRX LTD (0000093314) (Issuer)
4 - VOLITIONRX LTD (0000093314) (Issuer)
HENDERSON, Nev., Jan. 8, 2025 /PRNewswire/ -- VolitionRx Limited (NYSE:VNRX) ("Volition" or the "Company"), a multi-national epigenetics company, has issued a Business Review of 2024, outlining its key highlights from the past year. Volition's major achievements in 2024 include: Expanded access to the Nu.Q® Vet Cancer Test – now available for purchase in 20 countries worldwide.Sold over 110,000 Nu.Q® Vet Cancer Tests in the first three quarters 2024.Hosted Satellite Symposium at European Society of Intensive Care Medicine 2024 showcasing Nu.Q® NETs clinical utility in over 3,000 intensive care sepsis patients.Continued to strengthen our strategic patent portfolio.Made significant progress a
HENDERSON, Nev., Nov. 6, 2024 /PRNewswire/ -- VolitionRx Limited (NYSE:VNRX) ("Volition"), a multi-national epigenetics company, has appointed Timothy Still as Chairman of its board of directors, effective November 06, 2024. Mr. Still is currently Chairman and CEO of TSTILL Enterprises LLC, and an Operating Partner with REVIVAL Healthcare. An accomplished executive with a career spanning over 35 years in medical diagnostics, devices and digital health, his background includes extensive experience in designing and implementing highly focused commercial and business development
HENDERSON, Nev., Sept. 30, 2024 /PRNewswire/ -- VolitionRx Limited (NYSE:VNRX) ("Volition"), a multi-national epigenetics company, has appointed Dr. Ethel Rubin to its board of directors, as an independent director, effective September 30, 2024. Dr. Rubin has also been appointed as a member of the Audit Committee and the Compensation Committee. Dr. Rubin has over 20 years' experience within the life sciences sector, leading healthcare innovation and commercialization strategies for a wide range of organizations – from early-stage operations to large global corporate businesses
S-3 - VOLITIONRX LTD (0000093314) (Filer)
8-K - VOLITIONRX LTD (0000093314) (Filer)
D - VOLITIONRX LTD (0000093314) (Filer)
HENDERSON, Nev., July 8, 2025 /PRNewswire/ -- VolitionRx Limited (NYSE:VNRX) ("Volition"), a multi-national epigenetics company, today announces it has demonstrated quantification of nucleosomes in whole venous blood in minutes utilizing a simple lateral flow device. The blinded study, part of the SUMMIT program, tested blood samples from 25 hospital patients in Intensive Care or at the Emergency Department. The results correlated strongly with those of Volition's established automated central laboratory Nu.Q® nucleosome assay, demonstrating the feasibility of early detection of immune disruptions that can occur in a range of conditions including sepsis, simply and rapidly in a doctor's off
Peer Reviewed Clinical Study for H3.1 Biomarker Published in Critical Care HENDERSON, Nev., June 12, 2025 /PRNewswire/ -- VolitionRx Limited (NYSE:VNRX) ("Volition"), a multi-national epigenetics company, today announced the publication of a new clinical manuscript suggesting that the Nu.Q® H3.1 biomarker has the potential to inform clinical care in critically-ill Intensive Care Unit (ICU) patients in the assessment of sepsis, organ failure and subphenotypes. Dr. Andrew Retter, Chief Medical Officer, Volition said: "This independent peer-reviewed and published study (1713 patients) clearly demonstrates that Nu.Q® H3.1 is a clinically meaningful, biologically specific marker of NETosis, wit
HENDERSON, Nevada, June 4, 2025 /PRNewswire/ -- VolitionRx Limited (NYSE:VNRX) ("Volition"), a multi-national epigenetics company, today announces two oral presentations featuring its Nu.Q® Vet Cancer Test at the Asian Meeting of Animal Medicine Specialties (AMAMS 2025), a premier event bringing together leading veterinary professionals and experts from across Asia. The two presentations feature results from two clinical studies conducted by Dr Masahiko Sato, DVM, PhD, DACVIM (SAIM), DAiCVIM (IM) in conjunction with FujiFilm Vet Systems. Dr Sato, a key opinion leader is Chief of Internal Medicine Service at the Veterinary Specialists Emergency Center, one of the largest referral hospitals in
H.C. Wainwright initiated coverage of VolitionRx with a rating of Buy and set a new price target of $2.50
The Benchmark Company downgraded VolitionRx from Buy to Hold
Cantor Fitzgerald resumed coverage of VolitionRx with a rating of Overweight and set a new price target of $7.00 from $8.00 previously
4 - VOLITIONRX LTD (0000093314) (Issuer)
4 - VOLITIONRX LTD (0000093314) (Issuer)
4 - VOLITIONRX LTD (0000093314) (Issuer)
Conference call to discuss financial and operational results scheduled for Friday, May 16 at 8:30 a.m. U.S. Eastern Time HENDERSON, Nev., May 15, 2025 /PRNewswire/ -- VolitionRx Limited (NYSE:VNRX) ("Volition"), a multi-national epigenetics company, today announces financial results and a business update for the first quarter ended March 31, 2025. Volition management will host a conference call tomorrow, May 16 at 8:30 a.m. U.S. Eastern Time to discuss these results. Conference call details can be found below. Cameron Reynolds, President and Group Chief Executive Officer, said: "2025 is a pivotal year for Volition as we focus on commercializing our ground breaking Nu.Q® platform in the hum
Conference call to take place on Friday, May 16 at 8:30 a.m. U.S Eastern Time Henderson, Nev., May 12, 2025 /PRNewswire/ -- VolitionRx Limited (NYSE:VNRX) ("Volition") today announces that it will host a conference call on Friday, May 16 at 8.30 a.m. U.S. Eastern Time to discuss its financial and operating results for the first quarter of 2025 and to provide a business update. Details of this event can be found below. Event: VolitionRx Limited First Quarter 2025 Earnings and Business Update Conference CallDate: Friday, May 16, 2025 Time: 8:30 a.m. U.S. Eastern Time/2.30 p.m. Central European Time U.S. & Canada Dial-in: 1-877-407-9716 (toll free)U.K. Dial-in: 0 800 756 3429 (toll fr
Conference call to take place on Monday, March 31 at 4:30 p.m. U.S Eastern Time HENDERSON, Nev., March 25, 2025 /PRNewswire/ -- VolitionRx Limited (NYSE:VNRX) ("Volition") today announces that it will host a conference call on Monday, March 31 at 4.30 p.m. U.S. Eastern Time to discuss its financial and operating results for the fourth quarter and full fiscal year 2024, in addition to providing a business update. Details of this event can be found below. Event: VolitionRx Limited Full Fiscal Year 2024 Earnings and Business Update Conference CallDate: Monday, March 31, 2025Time: 4:30 p.m. U.S. Eastern Time U.S. & Canada Dial-in: 1-877-407-9716 (toll free)U.K. Dial-in: 0 800 756 3429 (toll fre
SC 13G - VOLITIONRX LTD (0000093314) (Subject)
SC 13G - VOLITIONRX LTD (0000093314) (Subject)
SC 13G/A - VOLITIONRX LTD (0000093314) (Subject)